LeMaitre Vascular Inc

LMAT remains in a Stage 2 advancing corrective reset with a clear long-term uptrend and medium-term bullish HH/HL structure, but is currently extended above its rising EMAs—preferring to defer entry and stalk pullbacks into the 9/21/50 EMA zone near prior breakout levels.

• ↑11% YoY revenue growth to $71.5M, gross margin up to 72.7%, EPS +42%.
• ↑International Autograph sales set to reach $10M in 2026, up from $4M.
• ↓Regulatory approval delays in Europe could stall Autograph launch timing.